Lyell Immunopharma, Inc. (LYEL)

3.3400 +0.0600 (+1.83%) At close: 04:00PM EST

Lyell Immunopharma, Inc.

201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://www.lyell.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 219

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Richard D. Klausner M.D.	Founder & Exec. Chairman	510.17k	N/A	1952
Dr. Lynn Seely M.D.	Pres, CEO & Director	32.67k	N/A	1959
Mr. Charles W. Newton	Chief Financial Officer	1.75M	N/A	1971
Mr. Stephen J. Hill	Chief Operating Officer	808.12k	N/A	1970
Ms. Elizabeth Homans	Consultant	988.85k	N/A	1966
Prof. Stanley R. Riddell M.D.	Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Crystal L. Mackall M.D.	Founder & Scientific Advisor	N/A	N/A	N/A
Nellie Dillery	Director of Accounting	N/A	N/A	N/A
Mr. Richard Goold Ph.D.	Chief Information Officer	N/A	N/A	1960
Dr. Gary Lee Ph.D.	Chief Scientific Officer	N/A	N/A	1977

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate governance

Lyell Immunopharma, Inc.’s ISS governance QualityScore as of 1 January 2023 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.